Related Experiment Video

Updated: May 21, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Third generation tyrosine kinase inhibitors and their development in advanced renal cell carcinoma

Ronald M Bukowski1

  • 1Cleveland Clinic Taussig Cancer Center, Cleveland Clinic Lerner College of Medicine of CWRU Pepper Pike, OH, USA.

Frontiers in Oncology
|June 2, 2012
PubMed

Insights

Next-generation tyrosine kinase inhibitors (TKIs) targeting the vascular endothelial growth factor (VEGF) pathway show promise for advanced renal cell carcinoma (RCC). These TKIs offer enhanced specificity and inhibition for improved treatment strategies.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • The vascular endothelial growth factor (VEGF) signaling pathway is a validated therapeutic target in renal cell carcinoma (RCC).
  • Clear-cell kidney carcinoma demonstrates sensitivity to VEGF pathway inhibitors.
  • Recent years have seen a paradigm shift in advanced RCC treatment, with six new agents approved since 2005.

Purpose of the Study:

  • To review the evolving data on next-generation tyrosine kinase inhibitors (TKIs) for advanced RCC.
  • To examine preclinical and clinical data for axitinib and tivozanib.
  • To provide an overview of TKI development and discuss their potential roles in RCC therapy.

Main Methods:

  • Review of preclinical and clinical data for axitinib and tivozanib.
  • Examination of the development of next-generation TKIs.
  • Discussion of potential therapeutic roles in advanced RCC.

Main Results:

  • The development of next-generation TKIs like axitinib and tivozanib aims for increased target specificity and enhanced inhibition.
  • These agents represent an evolution from earlier therapies like interferon-α and interleukin-2, and initial TKIs such as sunitinib, pazopanib, and sorafenib.

Conclusions:

  • Next-generation TKIs are being developed to offer improved efficacy and specificity in treating advanced RCC.
  • Further investigation into axitinib and tivozanib is warranted to define their role in the evolving treatment landscape of RCC.
Keywords:
renal cell carcinomatyrosine kinase inhibitors

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...